Compare Starbucks Corp (SBUX) vs GeneDx Holdings Corp (WGS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Starbucks Corp vs GeneDx Holdings Corp — how do they compare? Starbucks Corp trades at $108.35 (market cap $121.59B), while GeneDx Holdings Corp trades at $82 (market cap $2.44B). The key difference: Starbucks Corp is far larger — about 49.8× GeneDx Holdings Corp's market cap, and Starbucks Corp pays a 2.33% dividend while GeneDx Holdings Corp pays none. Which is the better fit depends on your goals.
| SBUX | WGS | |
|---|---|---|
Market Cap | $121.59B | $2.44B |
Volume | 7,493,833 | — |
Sector | Consumer Cyclical | Technology |
52-Week High | $108.49 | $167.51 |
52-Week Low | $78.46 | $34.51 |
Enterprise Value | $140.42B | $2.48B |
Dividend Yield | 2.33% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Starbucks (SBUX) trades at $108.03, up 3.23% with strong technical momentum and bullish moving average signals. The company shows improving fundamentals with recent earnings beats and raised 2026 guidance, though valuation remains elevated at a P/E of 61.65. Recent news highlights a successful turnaround strategy under CEO Brian Niccol, with traffic recovery and margin expansion driving optimism.
The outlook remains positive with analyst consensus pointing to $113.60 price target, though high valuation and execution risks require monitoring. Key opportunities include sustained traffic growth and cost efficiency initiatives, while risks involve premium pricing sensitivity and competitive pressures in the coffee retail space.
GeneDx Holdings Corp (WGS) trades at $82.39, up 5.79% in the past 24 hours, with a bullish technical signal and strong analyst support. The company reported Q2 2026 revenue of $114.4 million, beating guidance, and returned to adjusted profitability earlier than expected. However, net income remains negative at -$106 million for 2026, and the stock faces class action lawsuits with an August 3, 2026 deadline.
Outlook is mixed: bullish technicals and analyst consensus suggest upside to the $90 price target, but fundamental weaknesses and legal risks pose significant challenges. Investment opportunity hinges on sustained revenue growth and margin improvement, while risks include profitability pressures and litigation outcomes.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Starbucks Corp
Starbucks Corporation retails, roasts, and provides its own brand of specialty coffee. The Company operates retail locations worldwide and sells whole bean coffees through its sales group, direct response business, supermarkets, and on the world wide web. Starbucks also produces and sells bottled coffee drinks and a line of ice creams.
Read more on SBUX →About GeneDx Holdings Corp
GeneDx is a patient-centered health intelligence company that specializes in transforming healthcare through the application of genomics. It combines advanced technology with one of the world's largest rare disease genomic datasets to provide clinical-grade exome and genome sequencing, enabling precise and rapid diagnosis for patients with complex medical conditions.
Read more on WGS →
